BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Johnson & Johnson’s Heart Pump Trial Shows Promising Results for Cardiogenic Shock Patients
Johnson & Johnson’s Heart Pump Trial Shows Promising Results for Cardiogenic Shock Patients
16
1
BTCCSquare news:
Johnson & Johnson's Impella CP heart pump demonstrated a 16.3% reduction in mortality risk and extended life expectancy by 1.6 years for cardiogenic shock patients in its decade-long DanGer Shock trial. The findings, published in the New England Journal of Medicine, mark a significant advancement in cardiac care technology.
The healthcare giant simultaneously presented results at the European Society of Cardiology Congress, reinforcing its position in medical innovation. This development coincides with J&J's planned $55 billion U.S. investment expansion over four years, signaling strategic growth in domestic pharmaceutical manufacturing.
By:
